Back to top
more

Medtronic (MDT)

(Delayed Data from NYSE)

$92.88 USD

92.88
6,636,881

+1.64 (1.80%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $92.94 +0.06 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (155 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Boston Scientific Closes BTG Buyout, PI Arm to Get a Boost

by Zacks Equity Research

In its effort to accommodate the acquisition of BTG, Boston Scientific (BSX) is offloading its certain non-prior businesses.

Zacks Equity Research

Is Medtronic (MDT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (MDT) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Here's Why You Should Invest in NuVasive (NUVA) Stock Now

by Zacks Equity Research

Investor confidence is currently high on NuVasive's (NUVA) prospects.

Zacks Equity Research

Smith & Nephew (SNN) Hits a 52-Week High: What's Driving It?

by Zacks Equity Research

Smith & Nephew (SNN) has been gaining from several positive developments of late.

Zacks Equity Research

National Vision's Store Launches on Track Despite Cost Woes

by Zacks Equity Research

National Vision (EYE) adopts a formula-based approach to open around 75 stores in 2019.

Zacks Equity Research

ZBH vs. MDT: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ZBH vs. MDT: Which Stock Is the Better Value Option?

Zacks Equity Research

Edwards Lifesciences Sapien 3 System Recall Classified Class I

by Zacks Equity Research

Edwards Lifesciences (EW) initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the Sapien 3 Ultra delivery system.

Zacks Equity Research

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

by Zacks Equity Research

Investors' confidence continues to be high on solid prospects of Bio-Rad (BIO).

Zacks Equity Research

Abbott's Libre Adoption a Positive, Rhythm Management a Woe

by Zacks Equity Research

Abbott (ABT) is steadily riding high on a healthy growth track within its Diabetes Care business.

Zacks Equity Research

Zimmer Biomet Wins Nod for Spinal Teather to Treat Scoliosis

by Zacks Equity Research

Zimmer Biomet's (ZBH) AVBT solution, The Tether, uses a solid, flexible cord in place of traditional metal rods to pull on the outside of a scoliosis curve.

Zacks Equity Research

Genomic Health Test to Guide Chemo Per New Breast Cancer Rule

by Zacks Equity Research

This is a major development in Genomic Health's (GHDX) endeavor to strengthen its breast cancer treatment portfolio.

Zacks Equity Research

FDA OKs Medtronic's Evolut TAVR New Indication for Low Risk

by Zacks Equity Research

With the FDA's expanded indication nod, Medtronic's (MDT) Evolut TAVR platform now comes in handy for treating symptomatic severe aortic stenosis patients across all risk categories.

Zacks Equity Research

Company News For Aug 21, 2019

by Zacks Equity Research

Companies in the news are: KSS, MDT, BIDU and SRPT

Zacks Equity Research

Restoration Robotics (HAIR) Wins CE Mark for ARTAS iX System

by Zacks Equity Research

This regulatory approval is expected to strengthen Restoration Robotics' (HAIR) hair restoration business and expand its presence globally.

Zacks Equity Research

Medtronic (MDT) Beats on Q1 Earnings, Ups FY20 EPS Guidance

by Zacks Equity Research

Medtronic (MDT) displays improved performances at CER, banking on growth across all major segmental businesses as well as geographies.

Zacks Equity Research

Medtronic (MDT) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Medtronic (MDT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Walgreens (WBA) Expands Partnership With Retail Giant Kroger

by Zacks Equity Research

The extended partnership deal with Kroger will help Walgreens (WBA) strengthen its market presence.

Zacks Equity Research

Here's Why You Should Hold Onto IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Investor confidence continues to be high on IDEXX Laboratories' (IDXX) prospects.

Zacks Equity Research

Medtronic (MDT) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Medtronic (MDT) delivered earnings and revenue surprises of 6.78% and 1.11%, respectively, for the quarter ended July 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Zacks Analyst Blog Highlights: Cisco, Medtronic, Novo Nordisk, Southern and TransDigm

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Cisco, Medtronic, Novo Nordisk, Southern and TransDigm

Zacks Equity Research

Medtronic (MDT) to Post Q1 Earnings: Will RTG Aid the Stock?

by Zacks Equity Research

Medtronic (MDT) is encouraged by robust and consistent constant currency growth in the RTG business over the last few quarters.

Zacks Equity Research

Edwards Lifesciences' (EW) SAPIEN 3 TAVR Receives FDA Nod

by Zacks Equity Research

Edwards Lifesciences (EW) plans a commercial introduction of SAPIEN 3 Ultra in Europe.

Zacks Equity Research

Medtronic (MDT) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Medtronic's (MDT) successful execution of growth policies should aid earnings results in the fiscal first quarter.

Zacks Equity Research

Here's Why You Should Hold Onto Omnicell (OMCL) Stock for Now

by Zacks Equity Research

Investor confidence continues to be high on Omnicell's (OMCL) prospects.

Zacks Equity Research

QIAGEN Posts QIAstat-Dx Gastrointestinal Panel Study Results

by Zacks Equity Research

The study outcome has been a major step for QIAGEN (QGEN) toward offering accurate diagnosis and treatment of gastroenteritis.